Edition:
India

Genprex Inc (GNPX.OQ)

GNPX.OQ on NASDAQ Stock Exchange Capital Market

3.08USD
13 Jul 2020
Change (% chg)

$-0.03 (-0.96%)
Prev Close
$3.11
Open
$3.11
Day's High
$3.13
Day's Low
$3.06
Volume
52,811
Avg. Vol
439,352
52-wk High
$7.03
52-wk Low
$0.23

Latest Key Developments (Source: Significant Developments)

Genprex To Focus Its Clinical Efforts On Oncoprex In Combination Therapy With Osimertinib For Non-Small Cell Lung Cancer
Wednesday, 5 Feb 2020 

Feb 5 (Reuters) - Genprex Inc ::GENPREX TO FOCUS ITS CLINICAL EFFORTS ON ONCOPREX™ IN COMBINATION THERAPY WITH OSIMERTINIB FOR NON-SMALL CELL LUNG CANCER (NSCLC).GENPREX - PLANS TO FILE AMENDMENT TO INVESTIGATIONAL NEW DRUG APPLICATION WITH FDA FOR ONCOPREX & OSIMERTINIB COMBINATION THERAPY TRIAL WITHIN Q1 2020.GENPREX - PLANS TO INITIATE A PHASE I/II CLINICAL TRIAL OF ONCOPREX COMBINED WITH OSIMERTINIB IN MID-2020.  Full Article

Genprex Receives FDA Fast Track Designation For Gene Therapy That Targets Lung Cancer
Tuesday, 21 Jan 2020 

Jan 21 (Reuters) - Genprex Inc ::GENPREX RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR GENE THERAPY THAT TARGETS LUNG CANCER.GENPREX INC - PREPARING TO INITIATE A PHASE I/II CLINICAL TRIAL EVALUATING ONCOPREX IN COMBINATION WITH OSIMERTINIB.GENPREX INC - PREPARING TO INITIATE NEW PHASE I CLINICAL TRIAL EVALUATING ONCOPREX IN COMBINATION WITH A CHECKPOINT INHIBITOR.GENPREX - FDA GRANTED FAST TRACK DESIGNATION FOR CO'S ONCOPREX COMBINED WITH EGFR INHIBITOR OSIMERTINIB TO TREAT NON-SMALL CELL LUNG CANCER PATIENTS.  Full Article

Genprex Announces Resale Of Up To 3.6 Million Shares Of Co's Common Stock
Saturday, 28 Dec 2019 

Dec 27 (Reuters) - Genprex Inc ::GENPREX INC FILES PROSPECTUS RELATES TO RESALE BY CERTAIN SELLING STOCKHOLDERS OF UP TO 3.6 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING.  Full Article

Genprex Reports Positive Preclinical Data For The Treatment Of Lung Cancer
Tuesday, 19 Nov 2019 

Nov 19 (Reuters) - Genprex Inc ::GENPREX REPORTS POSITIVE PRECLINICAL DATA FOR THE TREATMENT OF SOME OF THE MOST RESISTANT METASTATIC LUNG CANCERS.GENPREX INC - TUSC2 IN COMBINATION WITH ANTI-PD1 AND CHEMOTHERAPY RESULTED IN COMPLETE ERADICATION OF ANTI-PD1 RESISTANT LUNG METASTASES.GENPREX - WHEN TUSC2 COMBINED WITH ANTI-PD1 THERAPY, PEMBROLIZUMAB THERE WAS SIGNIFICANTLY INCREASED ANTITUMOR ACTIVITY COMPARED TO EITHER AGENT ALONE.  Full Article

  • Previous
  • Next

Genprex Inc News

BRIEF-Genprex Receives USAN Approval Of Non-Proprietary Name For Lead Drug Candidate

* GENPREX RECEIVES USAN APPROVAL OF NON-PROPRIETARY NAME FOR LEAD DRUG CANDIDATE

» More GNPX.OQ News

Earnings vs. Estimates

» More Financials